[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574187":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Anhui Provincial Children's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Use of dolasetron mesylate injection to prevent nausea and vomiting induced by chemotherapy",null,"Subjects with childhood acute lymphoblastic leukemia treated with dolasetron mesylate injection for the prevention of nausea and vomiting induced by induction chemotherapy",[13],"Drug: Dolasetron mesylate injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Dolasetron mesylate injection","1.8 mg\u002Fkg Dolasetron mesylate injection should be injected intravenously 30±10 min before chemotherapy infusion, with the maximum dose not exceeding 100 mg. It can also be mixed with apple juice or apple-grape juice for oral use, the oral dose is 1.8 mg\u002Fkg, the maximum amount is not more than 100 mg, taken orally within 1 h before chemotherapy.\n\nOther antiemetic drugs, except dolasetron, are at the discretion of the subject's supervising physician in accordance with clinical practice.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Tianping Chen","CONTACT","（+86）13855189560","anhuichentp@163.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":10,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Anhui Children's Hospital","RECRUITING","Hefei","Anhui","China","CN",{"type":35,"coordinates":36},"Point",[37,38],117.28083,31.86389,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":43,"investigatorFullName":22,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Associate chief physician","100574187","dolasetron-for-the-prevention-of-cinv-in-children-with-acute-lymphoblastic-leukemia-100574187",false,"NCT06756022","Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia","Prospective, Multicenter, Real-world Study of Dolasetron Mesylate Injection for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children With Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n1. Age 2\\~17 years old\n2. The diagnosis of acute lymphoblastic leukemia was analyzed by comprehensive examination of bone marrow cell morphology, immune typing, cytogenetics and molecular biology.\n3. The subjects plan to receive induced remission therapy such as VDLP\u002FVDLD+CAM, multicenter CCCG ALL 2015 protocol, SCCCG-ALL-2023 protocol, etc. according to Guidelines for Diagnosis and Treatment of Childhood acute lymphoblastic Leukemia (2018 Edition) for the first time\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-2\n5. Expected to survive for more than 3 months\n6. Subject or guardian can read, understand and complete subject diary.\n\nExclusion Criteria:\n\n1. Allergic to Dolasetron mesylate injection and its excipients\n2. Patients with prolonged QTc interval (QT interval ≥460 ms)\n3. Other conditions considered by the researchers not to be included in the group.","ALL","2 Years","17 Years",{"count":56,"type":57},500,"ESTIMATED","1 Week","OBSERVATIONAL","This is a prospective, multicenter, real-world study of 500 participants with childhood acute lymphoblastic leukemia who are scheduled to receive dolasetron mesylate injection for prophylaxis against chemotherapy-induced nausea and vomiting.\n\nThis study did not make any decision or process intervention for clinical antitumor therapy. The study plans to observe the control of nausea and vomiting within 120 h (D1-D5) after receiving induction chemotherapy and the safety within 7 days (or until this discharge, whichever occurs first).\n\nDuring the whole study, demographic data, history of motion sickness, ECOG score, complications, name and dosage of anti-tumor therapy drugs, this antiemetic regimen, nausea and vomiting, rescue therapy drugs, combined drugs and adverse events were recorded.",[62],"Chemotherapy Induced Nausea and Vomiting","2024-12-30",{"date":65,"type":66},"2025-01-01","ACTUAL",{"date":68,"type":66},"2024-11-21",{"date":70,"type":57},"2025-12-31",{"name":5,"class":6},1]